The Future Is Non-Hormonal: Contraceptive Market Crawls Into The 21st Century
Early Stage Contraceptive Competitors Are Working On Hormone-Free Solutions
Despite patient dissatisfaction, contraceptive options have made little advancement since the turn of the century – but a cohort of novel, non-hormonal products could see this all change.
You may also be interested in...
Gedeon Richter has purchased a range of eight branded generic oral contraceptive drugs from Consilient Health for a consideration of over $40m, which it will now go on to market in the UK.
With cash preservation in mind, Rubius will dissolve, while EQRx, Impel, Cybin and Graphite cut jobs. Meanwhile, Jounce is restructuring and it plans to merge with Redx, yet the dually troubled firms MEI Pharma and Infinity will combine, while VBL will disappear in a reverse merger with Notable Labs.
The US Supreme Court’s overturning of Roe v. Wade, which enshrined the right to an abortion in the Constitution for almost 50 years, could have consequences that extend beyond access to termination of pregnancy.